Mouse Monoclonal FHIT Antibody

The FHIT (fragile histidine triad) gene, located at chromosome 3p14.2. is a tumor suppressor implicated in various cancers, including lung, gastric, and breast cancers. Discovered in 1996. FHIT encodes a diadenosine triphosphate hydrolase involved in purine metabolism and cell cycle regulation. Its inactivation—often due to genomic deletions, promoter hypermethylation, or transcriptional silencing—is linked to early carcinogenesis. FHIT antibodies are essential tools for detecting FHIT protein expression in research and diagnostics. These antibodies, typically monoclonal or polyclonal, enable techniques like immunohistochemistry (IHC), Western blotting, and immunofluorescence to assess FHIT loss in tumors, which correlates with poor prognosis. Studies suggest FHIT restoration may inhibit tumor growth, highlighting its therapeutic potential. However, commercial FHIT antibodies vary in specificity, requiring validation via knockout controls. Ongoing research explores FHIT's role in DNA damage response, apoptosis, and interactions with pathways like Wnt/β-catenin. Despite progress, challenges remain in standardizing FHIT detection and translating findings into clinical applications.